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Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap
of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine
phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients
with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received
21-day cycles of oral capecitabine (1250mgm
 2 twice daily on days 1–14) and docetaxel (75mgm
 2 i.v. on day 1). The patients
received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33–73 years). The overall response rate in the
38 efficacy-evaluable patients was 60% (95% confidence interval, 45–74%). The median progression-free survival was 5.2 months
(range, 1.0–15.5þ months) and the median overall survival was 10.5 months (range, 2.9–23.7þ months). The most common
grade 3/4 adverse events were hand–foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of
this combination are clearly warranted, albeit with lower doses of both agents (1000mgm
 2 twice daily and 60mgm
 2) to reduce
the rate of HFS and onycholysis.
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Gastric cancer remains one of the most common malignancies
worldwide (Parkin et al, 1999), and the leading cause of cancer
death in Korea (National Statistical Office, 2001). Despite
improvements in early diagnosis, many patients diagnosed with
gastric cancer are inoperable at the time of initial diagnosis.
Advanced gastric carcinoma (AGC) remains an incurable disease
with a median survival of only 6–9 months in patients receiving
chemotherapy. Therefore, there is a need for more effective
systemic therapy to improve the management of patients with
AGC.
The semisynthetic taxane docetaxel (Taxotere
s) is associated
with a high overall response rate, prolonged time to progression
(TTP) and acceptable tolerability in AGC, both as monotherapy
and in combination (Ridwelski et al, 2001; Haller and Misset,
2002). Results from several studies in Europe, the USA and Japan
have assessed first-line docetaxel monotherapy in AGC and
indicate that overall response rates range from 18 to 24% (Einzig
et al, 1996; Mai et al, 1998; Taguchi et al, 1998; Bang et al, 2002). A
number of studies have also investigated various docetaxel/5-FU
combinations in patients with recurrent AGC, with response rates
ranging from 28% (bolus 5-FU) to 44% (continuous infusional
5-FU), a median TTP of 5.9 months (bolus), and a median overall
survival of 7.7 months (bolus) (Constenla et al, 2002; Thuss-
Patience et al, 2003). Recently, presented data show that docetaxel
provides a small but significant survival benefit when added to
5-FU/cisplatin in AGC (Van Cutsem et al, 2003). However, poor
tolerability and a high rate of toxic deaths in this study make the
impact of this triplet combination questionable.
The oral fluoropyrimidine capecitabine (Xeloda
s) was designed
to generate 5-FU preferentially in tumour tissue and to mimic
continuous infusional 5-FU. This tumour selectivity is achieved
through exploitation of the significantly higher activity of
thymidine phosphorylase in many tumour tissues compared with
healthy tissue (Miwa et al, 1998; Schu ¨ller et al, 2000). Capecitabine
1250mgm
 2 twice daily on days 1–14 every 3 weeks has been
shown to be active (overall response rate 28%; stable disease 36%)
and well tolerated in a recent phase II study of previously
untreated patients with AGC (Hong et al, 2002). A 4-weekly
intermittent schedule of capecitabine (828mgm
 2 twice daily for 3
weeks followed by 1 week of rest) has also been shown to produce
overall response rates of 24% in a small, Japanese pilot phase II
study in patients with AGC (Koizumi et al, 2003). In a larger
Japanese clinical trial of 60 patients with previously untreated
AGC, the same intermittent schedule led to a response rate of 26%
and a median survival of 8.8 months (Kondo et al, 2003).
Preclinical studies in human cancer xenograft models demon-
strated that administration of docetaxel or paclitaxel results in
further upregulation of thymidine phosphorylase in human tissue
(Sawada et al, 1998). Coadministration of capecitabine or taxanes
in xenograft models resulted in synergistic antitumour activity,
whereas taxanes in combination with either 5-FU or uracil plus
tegafur demonstrated only additive efficacy (Sawada et al, 1998).
Since capecitabine mimics continuous infusional 5-FU and its
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lsafety profile differs from that of docetaxel with little overlap of
key toxicities, capecitabine combined with docetaxel is a more
compelling and convenient alternative to 5-FU/docetaxel.
The combination of docetaxel with other drugs, especially 5-FU
and cisplatin, is pharmacologically feasible in the management of
AGC and a number of regimens have been investigated in clinical
trials (Haller and Misset, 2002). Early data have also shown high
efficacy and manageable safety of 5-FU or capecitabine in
combination with docetaxel and cisplatin as first-line therapy
(Kang et al, 2003; Van Cutsem et al, 2003), which indicates the
feasibility of triple combinations in this setting. The potential to
improve safety and convenience by removing cisplatin to leave a
doublet (e.g. capecitabine and docetaxel) is also of interest in AGC,
particularly in light of the proven survival benefit of adding
capecitabine to docetaxel in second-line metastatic breast cancer
(O’Shaughnessy et al, 2002). Therefore, the objective of the current
phase II study was to investigate the feasibility, efficacy and safety
of capecitabine plus docetaxel in patients with previously
untreated AGC. We used the dosing schedule as described in a
previous phase I study for patients with advanced solid tumours
(Pronk et al, 2000).
MATERIALS AND METHODS
Patients
Patients were eligible if they had histologically confirmed advanced
or metastatic gastric adenocarcinoma with bidimensionally
measurable disease. This was defined as at least one tumour lesion
measuring X1.5 1.5cm with clearly defined margins on spiral
CT scan, MRI or abdominal ultrasound. Patients were X18 years
of age with an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2, and had received no prior chemother-
apy for metastatic disease. Adequate haematological (absolute
neutrophil count 41500ml
 1, platelets 4100000ml
 1), hepatic
(total bilirubin o1.5mgdl
 1, transaminase levels o3 times the
upper normal limit (UNL) or o5 times the UNL in cases of hepatic
metastases) and renal (creatinine o1.5mgdl
 1) functions were
required. The protocol was approved by the institutional review
board of the Korean Institute of Radiological and Medical Science,
and all patients gave written informed consent before enrolment.
Treatment schedule
Docetaxel 75mgm
 2 was administered as a 1-h intravenous
infusion on the first day of each 3-week cycle following
premedication with dexamethasone 8mg twice daily on days 0–2
for 3 days. Capecitabine was administered orally at a dose of
1250mgm
 2 twice daily according to the standard intermittent
schedule (14 days of treatment followed by a 7-day rest period).
Pyridoxine 300mgday
 1 was administered orally for 14 days for
the prevention of hand–foot syndrome (HFS).
Patients received at least two courses of capecitabine/docetaxel
unless rapid disease progression occurred after the first or second
course. Patients with response or stable disease received treatment
up to a maximum of six cycles or until progressive disease
occurred.
Dose modification for adverse events
Capecitabine treatment interruption or dose reduction was not
indicated for reactions unlikely to become serious or life
threatening, or for grade 1 toxicity (NCI-CTC, version 2.0).
Treatment was interrupted in cases of grade 2 or higher events
(with the exception of alopecia, nausea or vomiting and anaemia)
and was not resumed until the adverse effect resolved or improved
to grade 1 or 0. Capecitabine dose reduction was not required at
the first occurrence of a grade 2 event. Capecitabine dose was
reduced by 25% for patients who experienced a second occurrence
of a given grade 2 event or any grade 3 event. Capecitabine doses
were reduced by 50% for patients who experienced a third
occurrence of a given grade 2 event, a second occurrence of a given
grade 3 event, or any grade 4 event. Treatment was discontinued if,
despite dose reduction, a given adverse event occurred for a fourth
time at grade 2, a third time at grade 3, or a second time at grade 4.
If an adverse event did not improve to grade 1 or less after 3 weeks,
the affected patient was withdrawn from the study.
Docetaxel treatment was interrupted in cases of grade 2 or
higher event and was not resumed until the adverse effect resolved
or improved to grade 1 or 0. For patients who had developed grade
4 neutropenia for 47 days, or was associated with a temperature
of 4381C, a 25% permanent dose reduction was required. Patients
with grade 4 thrombocytopenia were retreated with a 25% dose
reduction after recovery. Treatment was discontinued in cases of
grade 3/4 neuropathy. Patients who developed hepatic function
abnormalities during therapy received a 25% dose reduction if
there was an increase in AST, ALT or alkaline phosphatase of
between 2.5 and 5  UNL. Elevations of any of these enzymes to
more than 5  UNL required docetaxel treatment to be suspended
for a maximum of 3 weeks; the patient was taken off the study if
they did not recover within that time frame.
Evaluation criteria
A physical examination, including a neurological examination and
complete blood counts, was performed before the first treatment
cycle. Pretreatment evaluation also included biochemical analyses,
chest X-ray and CT scans to define the extent of the disease.
Complete blood cell counts with differential and serum biochem-
istry analyses were repeated at each treatment cycle. Response was
assessed radiologically every two cycles or when progression was
suspected. Evaluations were performed by physical examination,
chest X-ray, abdomen-pelvis CT scan or ultrasonography.
Complete response (CR), partial response (PR), stable disease
(SD) and progressive disease (PD) were defined according to WHO
criteria.
Statistical analysis
The trial was designed using Gehan’s two-stage testing procedure.
Assuming a true response rate of X10%, 22 patients were initially
included. If at least one response was observed, enrolment would
then continue to 30 evaluable patients, with a target minimum
response of 30% and a maximum width of 36% for the 95%
confidence interval (CI). However, the number of patients enrolled
was increased to 42 to provide a more accurate estimate of
response rate. Progression-free survival (PFS) was calculated from
the first day of chemotherapy until the date of progression. Overall
survival was calculated from the start of the study treatment until
death. Progression-free survival and overall survival curves were
generated using the Kaplan–Meier method. Response duration
was calculated from the date of response confirmation to the date
of disease progression.
RESULTS
Patient characteristics
A total of 42 patients were enrolled between September 2001 and
March 2003. Baseline patient characteristics are listed in Table 1.
Of these, 41 patients were evaluable for safety and 38 for tumour
response. The median age of the 19 female and 23 male patients
was 53.5 years (range 33–73 years), and most of the patients (88%)
had a good performance status (ECOG 0 or 1). In all, 27 patients
(64%) had multiple metastases involving two or more organ
systems. The most common metastatic site was the abdominal
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llymph nodes (67%), and the most common metastatic organ was
the liver (36%). The median duration of follow-up at the time of
this analysis was 15.2 months (range 8.7–35.1 months).
Response to treatment
A total of 38 patients were evaluable for response. The remaining
four patients were not evaluable because of insufficient follow-up
data. The overall response rate was 60% (95% CI, 45–74%,
Table 2). Two (5%) patients achieved CR confirmed by gastro-
scopic biopsy. A total of 21 (55%) PRs were observed. The median
duration of response in the 23 responding patients was 6.8 months
(range 2.2–15.5 months). Six patients (14%) had disease stabilisa-
tion, and seven (17%) progressed while on treatment. The median
PFS and overall survival were 5.2 months (range 1.0–15.5þ
months) (Figure 1) and 10.5 months (range 2.9–23.7þ months)
(Figure 2), respectively, and the 1-year survival rate was 31%.
Safety
A total of 164 treatment cycles (median 4, range 1–6 cycles) were
administered, of which one was administered to the one patient
who was lost to follow-up. Haematological and nonhaematological
adverse events associated with treatment are listed in Table 3 and
Figure 3, respectively. The most common clinical adverse events
(all grades) were onycholysis (81%), HFS (76%), nausea/vomiting
(72%), stomatitis (45%) and neuropathy (31%). However, with the
exception of grade 3 HFS, which was seen in 50% of patients, grade
3/4 clinical adverse events were rare. While grade 1/2 haemato-
logical adverse events were relatively common, grade 4 neutrope-
nia was reported in only four patients (10%), neutropenic fever in
only three patients (7%) and grade 3 anaemia or thrombocytope-
nia were observed in 7% of patients each. There were no
treatment-related deaths.
Treatment delays or dose reductions were necessary in 57 out of
164 cycles. Doses were reduced in 52 cycles (32%) as a result of
neutropenia (9%), HFS (22%) and asthenia (1%). In addition, 26
patients (62%) had dose reductions for HFS. Treatment was
discontinued in two patients because of three episodes of grade 3
HFS. Treatment was delayed in five cycles (3%). The median dose
intensity for capecitabine and docetaxel were 84 and 88%,
respectively.
DISCUSSION
Previous large phase III studies comparing capecitabine with bolus
5-FU plus leucovorin as first-line therapy for metastatic colorectal
cancer have demonstrated the high single-agent activity and
Table 1 Patient characteristics
Characteristic Number of patients %
Number of patients enrolled 42
Evaluable for response 38
Evaluable for safety 41
Insufficient follow-up data 4
Age (years)
Median 53.5
Range 33–73
Sex
Male 23 55
Female 19 45
ECOG performance status
02 5
13 5 8 3
25 1 2
Metastatic site
Liver 15 36
Lung 3 7
Abdominal lymph node 28 67
Neck node 10 24
Peritoneum 5 12
Bone 3 7
Number of metastatic sites
11 5 3 6
22 0 4 8
X37 1 7
Table 2 Response to treatment
Response Number (n¼42) %
Confirmed response 23 60
CR 2 5
PR 21 55
SD 6 14
PD 7 17
Not assessable 4 10
CR¼complete response; PR¼partial response; SD¼stable disease and PD¼
progressive disease.
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Figure 1 Progression-free survival (n¼42).
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Figure 2 Overall survival (n¼42).
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lfavourable safety profile of capecitabine over 5-FU in a common
gastrointestinal cancer (Hoff et al, 2001; Van Cutsem et al, 2001;
Cassidy et al, 2002; Twelves et al, 2002). In addition, capecitabine-
based therapy has been shown to be active in first- and second-line
AGC, achieving response rates in the range of 20–55% (Kim et al,
2002; Hong et al, 2002; Tebbutt et al,2 0 0 2 ;K a n get al, 2003; Koizumi
et al, 2003). The addition of capecitabine to docetaxel has also been
shown to produce significant improvements in response rate, TTP
and overall survival with a manageable safety profile in metastatic
breast cancer (O’Shaughnessy et al, 2002; McDonald and Miles, 2003).
In our study, we found that the combination of docetaxel plus
capecitabine is highly active as first-line chemotherapy for AGC.
The response rate (60%), PFS (5.2 months) and overall survival
(10.5 months) in this trial were at the higher end of the range
reported in other phase II studies of doublets in AGC (Jeen et al,
2001; Cho et al, 2002). As would be expected, our results compare
favourably with findings on various docetaxel/5-FU combinations
in patients with recurrent AGC, where response rates ranged from
28% (bolus 5-FU) to 44% (continuous infusional 5-FU) (Constenla
et al, 2002; Thuss-Patience et al, 2003). In these studies of
pretreated patients, median TTP was approximately 5.9 months
(bolus), and median overall survival was around 7.7 months
(bolus). While the response rate achieved with docetaxel/
capecitabine in our study was good, the PFS and overall survival
times might have been expected to be higher. There were two
potential reasons for this: firstly, the maximum treatment duration
was limited to six cycles; secondly, the proportion of patients with
HFS (all grades) was very high (76%; grade 3, 50%), despite
administration of 300mg pyridoxine. This resulted in a reduction
in dose intensity of both agents. Therefore, we would recommend
starting dosing with lower doses of each drug (e.g. capecitabine
1000mgm
 2 twice daily; docetaxel 60mgm
 2), which have been
proven to be effective in various combination regimens. Further-
more, retrospective analysis of the O’Shaughnessy et al (2002)
study showed no reduction in efficacy when doses of capecitabine
and docetaxel were reduced because of adverse events from the
second cycle onwards (Professor C Twelves, personal communica-
tion).
While HFS was a major dose-limiting toxicity at the dosing level
we used, it is important to note that grade 3 HFS is not a life-
threatening adverse event. Most of the grade 2 or greater HFS was
also accompanied by onycholysis, which is a well-known adverse
effect of docetaxel that could be augmented by capecitabine.
Clearly, as mentioned above, the solution to these issues is to
reduce the doses of both agents in further studies of the
combination. Indeed, we are currently investigating this combina-
tion regimen with a reduced dose of capecitabine (1000mgm
 2
twice daily). However, reducing the docetaxel dose should further
improve safety and additional studies will be carried out to
evaluate different dosing regimens in AGC.
In conclusion, capecitabine plus docetaxel is highly active in
patients with previously untreated AGC. Further studies of this
combination are clearly warranted, albeit with lower doses of both
agents to reduce the rate of HFS and onycholysis. Capecitabine
alone is clearly unique among currently available treatments for
AGC in that it is compatible with oral, patient-oriented, home-
based therapy.
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